Marker Therapeutics (MRKR)
NASDAQ:MRKR
Want to see MRKR full AI Analyst Report?
Top Page
Marker Therapeutics
(NASDAQ:MRKR)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:Reiterated
Date:05/16/26
The score is primarily held down by weak financial performance—negative gross profit, ongoing losses, and sustained cash burn—despite low reported leverage. Technical signals are broadly neutral, and valuation is difficult to justify with negative earnings and no dividend. The recent authorization to substantially increase shares adds flexibility but increases dilution risk.
Positive Factors
Multi-antigen T‑cell therapy platform
Marker's multi-antigen adoptive T‑cell platform is a durable competitive asset: by targeting multiple tumor antigens it aims to reduce tumor escape and broaden applicability across hematologic and solid tumors, increasing long-term addressable markets and clinical utility.
Negative Factors
Negative gross profit and large losses
Persistent negative gross profit and sizable operating losses indicate the core activities are not yet economically viable. Over a 2–6 month horizon this undermines margin sustainability and implies continued reliance on funding until products can generate positive unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-antigen T‑cell therapy platform
Marker's multi-antigen adoptive T‑cell platform is a durable competitive asset: by targeting multiple tumor antigens it aims to reduce tumor escape and broaden applicability across hematologic and solid tumors, increasing long-term addressable markets and clinical utility.
Read all positive factors
Marker Therapeutics (MRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.34M
Dividend YieldN/A
Average Volume (3M)73.72K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-43.86%
EPS Growth49.21%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,673,126
10 Day Avg. Volume54,637
30 Day Avg. Volume73,715
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit-0.10
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$9.00Price Target Upside442.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$2.73M
Marker Therapeutics Business Overview & Revenue Model
Company Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumo...
How the Company Makes Money
null...
Marker Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 0.00 | 6.59M | 3.31M | 3.51M | 1.24M |
| Gross Profit | -2.08M | 0.00 | -6.88M | -7.11M | -8.45M | -1.92M |
| EBITDA | -12.22M | -12.44M | -11.12M | -11.79M | -17.00M | -38.72M |
| Net Income | -10.90M | -12.16M | -10.73M | -8.24M | -29.93M | -41.88M |
Balance Sheet | ||||||
| Total Assets | 17.43M | 19.07T | 22.02M | 17.13M | 34.42M | 68.14M |
| Cash, Cash Equivalents and Short-Term Investments | 14.92M | 16.07T | 19.19M | 15.11M | 11.78M | 42.35M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | 11.87M |
| Total Liabilities | 3.64M | 2.27T | 3.46M | 3.07M | 14.82M | 24.15M |
| Stockholders Equity | 13.80M | 16.80T | 18.56M | 14.05M | 19.60M | 43.99M |
Cash Flow | ||||||
| Free Cash Flow | -7.92M | -12.01T | -10.91M | -16.44M | -26.97M | -30.41M |
| Operating Cash Flow | -7.92M | -12.01T | -10.91M | -16.44M | -26.97M | -27.28M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 18.66M | -4.95M | -3.13M |
| Financing Cash Flow | 9.86M | 9.86T | 14.99M | 1.11M | 202.13K | 52.56M |
Marker Therapeutics Technical Analysis
Negative
1.66
Price Trends
1.45
Negative
1.55
Negative
1.32
Positive
Market Momentum
-0.02
Positive
44.11
Neutral
33.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.44, above the 50-day MA of 1.45, and above the 200-day MA of 1.32, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.11 is Neutral, neither overbought nor oversold. The STOCH value of 33.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRKR.
Marker Therapeutics Risk Analysis
Marker Therapeutics disclosed 55 risk factors in its most recent earnings report. Marker Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Marker Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.10M | -0.99 | -71.27% | ― | -55.97% | -198.81% | |
49 Neutral | $12.75M | -1.84 | ― | ― | ― | 80.65% | |
49 Neutral | $28.16M | -1.58 | -112.05% | ― | ― | 94.17% | |
44 Neutral | $23.34M | -1.97 | >-0.01% | ― | -43.86% | 49.21% | |
43 Neutral | $29.64M | -3.96 | -88.89% | ― | -100.00% | -170.04% | |
42 Neutral | $91.41M | -7.35 | -53.86% | ― | -20.00% | 75.26% |
* Healthcare Sector Average
MRKR
Marker Therapeutics
1.40
0.26
22.81%
IBIO
Ibio
1.84
1.02
124.94%
MBRX
Moleculin Biotech
2.39
-21.38
-89.95%
ABVC
ABVC BioPharma
1.14
-0.24
-17.39%
ADXN
Addex Therapeutics
6.83
-1.53
-18.30%
ALLR
Allarity Therapeutics
1.77
0.82
86.32%
Marker Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Marker Therapeutics Shareholders Approve Governance and Capital Changes
Positive
May 4, 2026
At its May 1, 2026 annual meeting, Marker Therapeutics’ shareholders re-elected all five director nominees and approved, on an advisory basis, executive compensation, while also ratifying CBIZ CPAs P.C. as the independent auditor for the 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.